Prion infections and anti-PrP antibodies trigger converging neurotoxic pathways

PLoS Pathog. 2015 Feb 24;11(2):e1004662. doi: 10.1371/journal.ppat.1004662. eCollection 2015 Feb.

Abstract

Prions induce lethal neurodegeneration and consist of PrPSc, an aggregated conformer of the cellular prion protein PrPC. Antibody-derived ligands to the globular domain of PrPC (collectively termed GDL) are also neurotoxic. Here we show that GDL and prion infections activate the same pathways. Firstly, both GDL and prion infection of cerebellar organotypic cultured slices (COCS) induced the production of reactive oxygen species (ROS). Accordingly, ROS scavenging, which counteracts GDL toxicity in vitro and in vivo, prolonged the lifespan of prion-infected mice and protected prion-infected COCS from neurodegeneration. Instead, neither glutamate receptor antagonists nor inhibitors of endoplasmic reticulum calcium channels abolished neurotoxicity in either model. Secondly, antibodies against the flexible tail (FT) of PrPC reduced neurotoxicity in both GDL-exposed and prion-infected COCS, suggesting that the FT executes toxicity in both paradigms. Thirdly, the PERK pathway of the unfolded protein response was activated in both models. Finally, 80% of transcriptionally downregulated genes overlapped between prion-infected and GDL-treated COCS. We conclude that GDL mimic the interaction of PrPSc with PrPC, thereby triggering the downstream events characteristic of prion infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies* / immunology
  • Antibodies* / toxicity
  • Mice
  • Mice, Transgenic
  • PrPSc Proteins / genetics
  • PrPSc Proteins / immunology*
  • Prion Diseases / chemically induced*
  • Prion Diseases / genetics
  • Prion Diseases / immunology*
  • Prion Diseases / pathology
  • Reactive Oxygen Species / immunology
  • Signal Transduction / drug effects*
  • Signal Transduction / genetics
  • Signal Transduction / immunology*
  • eIF-2 Kinase / genetics
  • eIF-2 Kinase / immunology

Substances

  • Antibodies
  • PrPSc Proteins
  • Reactive Oxygen Species
  • PERK kinase
  • eIF-2 Kinase

Associated data

  • GEO/GSE65147

Grants and funding

AA is the recipient of an Advanced Grant of the European Research Council (ERC: 250356 http://erc.europa.eu/advanced-grants and is supported by grants from the European Union (PRIORITY: 222887, NEURINOX: 278611; http://cordis.europa.eu/fp7/home_en.html), the Swiss National Foundation (SNF: 31003A_141193 and Sinergia with F. Helmchen and B. Schneider: CRSI33_125073; http://www.snf.ch/en/Pages/default.aspx), the Novartis Research Foundation, and the Clinical Research Priority Program (CRPP Small RNAs and CRPP Human Hepato-Lymphatic Diseases; http://www.uzh.ch/research/priorityprograms/clinic_en.html) of the University of Zurich. USH is supported by an MD/PhD grant of the Swiss National Foundation (323530-133900; http://www.snf.ch/en/Pages/default.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.